Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 15/20 | 0.59 |
| ▸ | EGFR | P00533 | 11/20 | 0.59 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | STK4 | Q13043 | 1/20 | 0.53 |
| ▸ | STK3 | Q13188 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27751267 | 0.87 | ERBB2 (0.58) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL23859935 | 0.86 | ERBB2 (0.57) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL6957850 | 0.85 | ERBB2 (0.56) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL22967411 | 0.85 | ERBB2 (0.56) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL31084744 | 0.83 | ERBB2 (0.74) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL9719862 | 0.83 | ERBB2 (0.74) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL22967633 | 0.82 | ERBB2 (0.53) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL20548962 | 0.82 | ERBB2 (0.59) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL9719782 | 0.82 | ERBB2 (0.53) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL2760112 | 0.81 | SYK (0.59) | ERBB2EGFRERBB3ERBB4LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760633-B1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2021-12-15 | — | — | EP | disclosed |
| EP-3760633-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-01-06 | — | — | EP | disclosed |
| WO-2019170088-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | 北京赛特明强医药科技有限公司 | 2019-09-12 | — | — | WO | disclosed |
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | disclosed |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| WO-2017114500-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | 恩瑞生物医药科技（上海）有限公司 | 2017-07-06 | — | — | WO | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-5157039-A | Lipoxygenase inhibitors | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1992-10-20 | — | — | US | disclosed |
| US-5109009-A | QUINOLINE AND PYRIDINE COMPOUNDS AND INHIBITION OF 5-LIPOXYGENASES THEREWITH | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1992-04-28 | — | — | US | disclosed |
| US-4826987-A | Pyridyl and quinoline derivatives | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | EGFR, ABL1, CSNK1A1 | ERBB2 4/4885EGFR 1/4885ERBB3 8/4885 |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | EGFR, ABL1, CSNK1A1 | ERBB2 4/4885EGFR 1/4885ERBB3 8/4885 |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | ERBB2 1/4885EGFR 2/4885ERBB3 4/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | ERBB2 1/4885EGFR 2/4885ERBB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.